Showing posts with label asthma. Show all posts
Showing posts with label asthma. Show all posts

Friday, 9 December 2011

Popular asthma drug inadequate when used alone

A drug widely prescribed as the sole treatment for asthma has been found to be incapable by itself when it comes to preventing asthma attacks.
The drug is also ineffective in controlling the airway inflammation thought to lead to deteriorated lung function and gradual worsening of asthma.
From Ucsf.edu:
“Inhaled steroids are widely underutilized,” Lazarus concludes. “In low doses they are safe, and they are the most proven method of attacking the inflammation that is asthma’s greatest long-term danger.”
Lazarus is co-author of a companion article in the same issue of JAMA which found that once their asthma was brought under control with inhaled steroids and long-acting beta agonists, most patients with more severe asthma could cut their steroid dosage in half with no ill effects. But if the steroids were dropped completely, the asthma could not be adequately controlled.
The study was funded by the National Heart, Lung and Blood Institute.

Friday, 31 December 2010

Asthma victims can benefit from steroids

According to a new study by researchers at Washington University School of Medicine and other institutions, asthmatics can benefit to a significant extent when doses of steroids are increased or more drugs are added to the steroid treatment.
Robert C. Strunk, M.D., and Leonard B. Bacharier, M.D., both Washington University pediatric asthma specialists at St. Louis Children's Hospital were co-authors for this study.
"We used a few complicated and expensive tests we thought would help us determine which drug would be better, but they didn't help, so we can avoid these tests," says Strunk, the Donald Strominger Professor of Pediatrics at Washington University School of Medicine.
Although 98 percent of patients in the study showed improvement on at least one of the step-up options, there were still 120 asthma exacerbations, or attacks, among the 165 patients that required treatment with prednisone, a corticosteroid commonly used after an exacerbation that prevents the release of inflammatory substances in the body. Bacharier says that indicates none of these treatments provide perfect asthma control.
"There may not be an ideal therapy for every patient, but these step-up treatments allow for improved asthma control and outcomes over leaving them on low-dose steroids alone," Bacharier says.
This study was published online March 2, 2010, by the New England Journal of Medicine and presented the same day at the American Academy of Allergy, Asthma and Immunology's annual meeting in New Orleans.

Wednesday, 25 August 2010

Cells mediating steroid-resistant asthma identified

Researchers at Children's Hospital of Pittsburgh of UPMC have been able to identify cells that can play a critical role in some forms of steroid-resistant asthma, which is a complication of the condition that makes treatment even more challenging.
The study was published in an issue of the Journal of Immunology.
More than 22 million Americans (including 9 million children) are diagnosed with asthma, according to the U.S. Centers for Disease Control and Prevention (CDC). As many as 50 percent of them have asthma that can be resistant to steroids, which are intended to reduce lung inflammation during an asthma attack, Dr. Kolls said.
"Asthma is a challenging condition to treat. For many patients, if they take preventive medications regularly, the condition can be controlled and they can lead relatively normal lives," Dr. Kolls said. "Inhaled steroids are an important treatment for patients to prevent asthma attacks. Unfortunately, some patients have attacks despite the use of inhaled steroids, meaning they don't respond to steroids or they need such high doses that side effects are experienced."
It was remarked by study's senior author, Jay K. Kolls, MD, chief of the Division of Pediatric Pulmonary Medicine, Allergy and Immunology at Children's Hospital that discovery of a lineage of cells known as T Helper Type 17 (Th17) can be useful in helping scientists to develop new treatments and exercise a better control on the disease.

Thursday, 29 July 2010

Physicians could predict cause of hospital readmission among newborns

Physicians can easily prevent complications in context to newborns and relieve worries of parents via genetic testing, according to results of two separate studies conducted at Children's Mercy Hospitals and Clinics. This form of testing could be effectively used to make predictions in advance as to which all of their newborn patients would be requiring hospital readmission shortly after birth.
The study results are considered to assist physicians to examine which of all their young patients will be responding well or not to therapy involving steroids for treating asthma.
Up to 85 percent of hospital readmissions during the first two weeks of life are due to hyperbilirubinemia, more commonly recognized as jaundice. The condition can be concerning for new parents, and potentially devastating for the infant if not recognized and promptly treated. New research being led by Susan Abdel-Rahman, PharmD, professor of pediatrics at Children's Mercy Hospitals and Clinics is identifying specific genetic markers that will enhance the ability to predict which newborns are at risk.
"This condition can be very harmful for newborn infants and scary for new parents," said Dr. Abdel-Rahman. "Knowing in advance which babies are likely to experience symptoms can provide reassurance for parents and guidance for clinicians in determining which babies may benefit from more careful monitoring."
The goal of the research is to develop an electronic tool that can be used by clinicians in nurseries nationwide to dramatically improve prediction of risk for hyperbilirubinemia and prevent complications due to late detection. The study will be among the largest of its kind, aiming to enroll 3,500 newborns.
The research was led by Bridgette L. Jones, MD, allergy, asthma and immunology and clinical pharmacology specialist, and Carrie A. Vyhlidal, PhD, research scientist, pediatric clinical pharmacology, at Children's Mercy Hospitals and Clinics, and a separate study was conducted by researchers at Children's Mercy.

Sunday, 20 June 2010

Pregnant women can use steroids without side effects

According to a study, pregnant women suffering from asthma can continue using steroids without affecting growth of their unborn babies.
It was disclosed by the involved researchers that unborn babies are in far more danger from lack of oxygen than the mother making use of inhaled steroids.
The researchers looked at 396 pregnant women who took inhaled steroids. It did not have an effect on the growth of the fetus. There was no effect on the baby's birth weight either.
They also found that inhaled steroids are safer for pregnant women to take than steroid pills. Oral steroids have been shown to slow the fetus' growth. Oral steroids are also used to treat asthma.
The study was carried out at the Kaiser-Permanente Medical Center in San Diego. The team leader was Michael Schatz.
Schatz said 'Now, women don't have to make a choice between their health and the health of the baby. They don't have to think that making that choice is going to somehow harm the baby.'
You can read about the study in the Journal of Allergy and Clinical Immunology.
7% of pregnant women get asthma to some degree. Some of these women use inhaled steroids. The National Asthma Education and Prevention Program, (part of the Department of Health and Human Services), supports the use of steroids in pregnant women with serious asthma.
The worry asthmatic women have when they are pregnant is that the fetus is deprived of oxygen. This can sometimes lead to retardation, premature birth, low birth weight and even stillbirth.
The study results appeared in the Journal of Allergy and Clinical Immunology.

Sunday, 13 June 2010

Some children might be 'unlucky' with asthma medications

Children and girls exposed to tobacco smoke could derive more benefit from one of the most widely prescribed medications for asthma and allergies, Montelukast.
The finding was revealed by researchers at National Jewish Medical and Research Center and appeared in an issue of the Journal of Allergy and Clinical Immunology.
Inhaled corticosteroids are considered the first-line treatment for cases of persistent asthma. However, steroids alone do not effectively control asthma in 30 percent to 40 percent of patients and they may have some side effects, especially in children. In those cases, a secondary medication is often used. Montelukast is one such medication.
Montelukast, one of the most widely prescribed medications for asthma and allergies, blocks the action of chemicals called leukotrienes, which contribute to inflammation. However, physicians have found that montelukast is quite variable in its effectiveness, helping some patients but not others. Dr. Rabinovitch and his colleagues set out to better understand its variable effectiveness.
Two biomarkers were discovered by Associate Professor of Pediatrics Nathan Rabinovitch, MD, and his colleagues that can prove helpful to physicians in accurately determining as to which all of their asthmatic patients can benefit from montelukast.

Monday, 24 May 2010

Asthma drug combo or increase in steroid doses can bring improvement

Children with asthma and continuing to experience the disease symptoms and making use of use of low-dose inhaled corticosteroids can find benefit by or adding one of two asthma drugs or increasing the dosage.
Results of the study, called BADGER (Best ADd-on therapy Giving Effective Responses) can help physicians in predicting, in a better way, as to which of the options would help a patient the most.
Surprisingly, researchers determined several factors that had no influence on a drug's effectiveness, including age, gender, allergies, bronchodilator response, recent exacerbations or several other tests.
"We used a few complicated and expensive tests we thought would help us determine which drug would be better, but they didn't help, so we can avoid these tests," says Strunk, the Donald Strominger Professor of Pediatrics at Washington University School of Medicine.
Although 98 percent of patients in the study showed improvement on at least one of the step-up options, there were still 120 asthma exacerbations, or attacks, among the 165 patients that required treatment with prednisone, a corticosteroid commonly used after an exacerbation that prevents the release of inflammatory substances in the body. Bacharier says that indicates none of these treatments provide perfect asthma control.
"There may not be an ideal therapy for every patient, but these step-up treatments allow for improved asthma control and outcomes over leaving them on low-dose steroids alone," Bacharier says.
Robert C. Strunk, M.D., and Leonard B. Bacharier, M.D., both Washington University pediatric asthma specialists at St. Louis Children's Hospital, were coauthors on the study, published online March 2, 2010, by the New England Journal of Medicine.

Friday, 2 April 2010

Management of asthma among preschoolers

Asthma is the commonest of all chronic diseases in children and a major reason for admission to hospital still there is lack of asthma control in 26 to 45 percent of children, as per a review in CMAJ(Canadian Medical Association Journal.
The review provided invaluable insights for differentiating between transient asthma and chronic asthma in preschoolers and information on managing both types.
For children with intermittent asthma, using inhaled corticosteroids only during attacks does not appear to be effective. Regular therapy with inhaled steroids should be used for children with more severe intermittent or persistent symptoms. Treatment with leukotriene receptor antagonists during the viral season may help to reduce symptoms and visits to health care providers. The possibility of another condition should be considered if children do not respond to optimal therapy.
The study authors stated that more research is needed for examining the effectiveness of asthma treatment options among young children.

Tuesday, 9 March 2010

Decline of lung function can be halted with Vitamin D

Vitamin D emerges as an effective option for slowing down the progressive decline in the ability to breathe in asthmatic people due to human airway smooth muscle (HASM) proliferation.
The finding was reported by researchers at the University of Pennsylvania. It was remarked by the researchers that calcitriol, a form of vitamin D synthesized within the body, can prove effective to reduce growth-factor-induced HASM proliferation in cells isolated from both persons with asthma and from persons without the disease.
"Calcitriol has recently earned prominence for its anti-inflammatory effects," said Gautam Damera, Ph.D., who will present the research at the American Thoracic Society's 105th International Conference in San Diego on May 20. "But our study is the first to reveal the potent role of calcitriol in inhibiting ASM proliferation."
The experiments were conducted with cells from 12 subjects, and the researchers compared calcitriol with dexmethasone, a corticosteroid prescribed widely for the treatment of asthma. Although, dexmethasone is also a powerful anti-inflammatory agent, the researchers found that it had little effect on HASM growth.
Dr. Damera and his colleagues found calcitriol inhibits HASM in a dose-dependent manner, with a maximum inhibitory effect of 60 percent ± 3 percent at 100nM.
The irreversible decline in breathing leading to vulnerable health in asthmatics is possible of being prevented or forestalled by slowing airway remodeling, as per the researchers.